MetaCap

Prelude Therapeutics (PRLD) vs Relmada Therapeutics (RLMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Prelude Therapeutics (PRLD) has outperformed Relmada Therapeutics (RLMD) over the past year, gaining 93.4% versus a loss of 38.6%. Over five years, PRLD leads with a -76.9% price change compared with -86.1% for RLMD. Relmada Therapeutics is the larger company by market cap ($279.5 million vs $258.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PRLD+93.41%RLMD-38.64%
+314%+129%-55%
Nov 21, 20251 yearNov 20, 2026
PRLD-77.66%RLMD-87.15%
+91%-9%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PRLD versus RLMD key metrics
MetricPRLDRLMD
Share price$3.23$2.62
Market cap$258.63M$279.54M
1-day change-0.77%-15.76%
YTD return+11.38%-45.76%
1-year return+93.41%-38.64%
5-year return-76.93%-86.09%
EPS (TTM)$-0.59$-0.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$12.14M—
Revenue growth (YoY)+73.43%—
Net income (latest FY)$-99.50M$-57.39M
Operating margin-861.33%—
Net margin-819.59%—
52-week high$6.83$8.00
52-week low$1.30$2.60
Distance from 52-week high-52.71%-67.25%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+172.45%+310.31%
Average volume432.74K1.45M
Shares outstanding65.34M106.69M
Employees7917
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PRLD has outperformed RLMD by 132.1 percentage points over the past year.

About Prelude Therapeutics

PRLD stock →

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.

Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees

About Relmada Therapeutics

RLMD stock →

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

PRLD vs RLMD FAQ

Which is bigger, Prelude Therapeutics or Relmada Therapeutics?

Relmada Therapeutics (RLMD) is larger, with a market capitalization of $279.54M compared with $258.63M for Prelude Therapeutics (PRLD).

Which stock has performed better over the past year, PRLD or RLMD?

PRLD returned +93.41% over the past 12 months, compared with -38.64% for RLMD (price return, excluding dividends). Past performance does not predict future results.

Are Prelude Therapeutics and Relmada Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons